Compressing drug development timelines in oncology using phase '0' trials.

Nat Rev Cancer 2007 02;7(2):131-9

Center for Cancer Research, SAIC-Frederick, Inc., NCI-Frederick, Frederick, Maryland, USA.

The optimal evaluation of molecularly targeted anticancer agents requires the integration of pharmacodynamic assays into early clinical investigations. Phase '0' trials conducted under the new Exploratory Investigational New Drug Guidance from the US Food and Drug Administration can provide a platform to establish the feasibility of assays for target modulation in human samples, evaluate biomarkers for drug effects and provide pharmacokinetic data. Phase 0 trials could facilitate rational drug selection, identify therapeutic failures early, and might compress timelines for anticancer drug development. We expect that such trials will become a routine part of early-phase oncological drug development in the future.

Download full-text PDF

Source
http://dx.doi.org/10.1038/nrc2066DOI Listing
February 2007
7 Reads

Publication Analysis

Top Keywords

drug development
12
phase '0'
8
'0' trials
8
drug
6
samples evaluate
4
human samples
4
modulation human
4
evaluate biomarkers
4
drug effects
4
pharmacokinetic data
4
provide pharmacokinetic
4
effects provide
4
target modulation
4
biomarkers drug
4
assays target
4
food drug
4
guidance food
4
drug guidance
4
investigational drug
4
drug administration
4

Altmetric Statistics

References

(Supplied by CrossRef)

I Kola et al.
Nature Rev. Drug Discov. 2004

JI Johnson et al.
Br. J. Cancer 2001

H Olson et al.
Regul. Toxicol. Pharmacol. 2000

JE Tomaszewski et al.
2001

E Fox et al.
Oncologist. 2002

AW Millar et al.
Nature Rev. Cancer. 2003

ML Rothenberg et al.
Nature Rev. Cancer. 2003

S Kummar et al.
Br. J. Clin. Pharmacol. 2006

P Workman et al.
J. Natl Cancer Inst. 2006

Similar Publications